XNOM Xenomics Inc. featured news, full reports, and detailed charts
Xenomics Inc. (XNOM/XNOM.PK) Wrap Up:
Xenomics, Inc. operates as a development stage molecular diagnostic company. It focuses on the development of DNA-based tests using transrenal DNA or Tr-DNA. Tr-DNAs are fragments of DNA derived from dying cells inside the body compartment. The company’s technology is applied in a range of testing, including prenatal genetic testing, tumor detection and monitoring, tissue transplantation, infectious disease, forensic identification, drug development, and bio-terrorism. It has a joint venture with the Spallanzani National Institute for Infectious Diseases to conduct research and development on noninvasive diagnostic tests for infectious disease using Tr-DNA methodology. The company was incorp...Xenomics Inc. (XNOM:OTC)
|
Market Cap
13.7M
|
Total Revenue
--
|
|
|
EBITDA
6.9M
|
DILUTED EPS TTM
-0.36
|
|
|
P/E
--
|
P/S
--
|
|
|
Return On Asset
-144.45
|
Return On Equity
-277.69
|
|
| K = Thousands M = Millions B = Billions | ||
XNOM Top Compensated Officers
Executives, Board Directors
Key developments for Xenomics Inc. (XNOM)
Xenomics Inc. and TrovaGene Inc. announced that they have filed a patent application on novel technology for the detection of Human Papilloma Virus (HPV) DNA, based on Xenomics transrenal DNA technology. The technology would be applied to urine-based HPV screening.
Xenomics Inc. announced the appointment of Bruce A. Huebner, a veteran of the diagnostics industry, as Chief Executive Officer and board director. Mr. Huebner has over 35 years of experience in the diagnostic industry, and has been a key member of upper management in a number of clinical diagnostic companies including Hybritech Inc., Gen-Probe Inc., Nanogen Inc. and Osmetech Molecular Diagnostics. Concurrent with Mr. Huebner's appointment, Xenomics announced the formation of TrovaGene Inc., a wholly owned subsidiary, under the laws of the State of Delaware, and plans to change the name of the company to 'TrovaGene'. The planned name change, by statutory merger, will be proposed to shareholders in the next 30 to 60 days. TrovaGene, under Mr. Huebner's guidance, will be engaged in refocusing the company's development and partnering programs.
Xenomics Inc. has removed Donald H. Picker, Ph.D. as a director.
XNOM Competitors
| Company | Last | Change | |
| No competitor information is available for XNOM. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | XNOM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
XNOM |
||
XNOM transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||